Overall, glucose-lowering therapy was not significantly associated with a reduction in all-cause dementia or cognitive impairment. Treatment with glucagon-like peptide-1 receptor agonists (GLP ...

GLP-1RA versus other second-line glucose-lowering drugs SGLT2i versus other second-line glucose-lowering drugs GLP-1RA versus SGLT2i. The scientists concluded that GLP-1RAs and SGLT2is were ...

or sodium–glucose cotransporter 2 inhibitors), diuretics and dietary sodium restriction, and additional agents as needed to treat hypertension and hyperlipidemia. In patients with clinically ...

Patients with type 2 diabetes may have the lowest risk of progressing to moderate chronic kidney disease (CKD) and kidney failure when they use a sodium-glucose cotransporter 2 inhibitor (SGLT2i) or ...

The glucose tolerance test screens for gestational diabetes during pregnancy. Typically, your doctor or medical professional will ask you to have a glucose screening test first. Depending on the ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a significantly lower risk of dementia and Alzheimer's disease ...

Accelerate your tech game Paid Content How the New Space Race Will Drive Innovation How the metaverse will change the future of work and society Managing the Multicloud The Future of the Internet ...

The US study analysed data from type 2 diabetes patients taking either GLP-1 receptor agonists (GLP-1RAs) or sodium-glucose cotransporter-2inhibitors (SGLT-2i). GLP-1RAs like semaglutide work by ...

Designed for individuals who may struggle with maintaining optimal glucose levels, this product harnesses the power of natural ingredients that have been scientifically studied for their efficacy.

Semaglutide in particular, whose brand names include Wegovy and Ozempic, showed promise in cutting the risk of conditions that impair memory and thought processes, according to researchers.